Personalised Medicine Strategies – Providing More Clinical Benefit
4 years ago
By Ben Parkes
Current personalised medicine strategies provide limited clinical benefit – how do we do better?
Luckily Dr Allan Jordan, the Director of Oncology Drug Discovery at leading CRO Sygnature Discovery, was on hand to explain how. Here’s another chance to watch his fascinating keynote presentation, packed full of fresh insights, data and takeaways.
The next chance to here the latest clinical insights, including more on personalised medicine strategies, will be at our clinical Online Strategy Meetings in November. For more information check out the links below:
Clinical Operations Strategy Meeting – November 16
Clinical Trial Supply Chain Strategy Meeting – November 18
Pharmacovigilance Strategy Meeting – November 19
How to Reduce the Cost of Clinical Trial Supply Chain While Maintaining Quality and Efficiency
Clinical trial supply chain is a critical component of drug development, ensuring that drugs are available for testing, regulatory approval, and distribution. However, managing this supply chain can be challenging, with factors such as cost, quality, and efficiency all coming...
1 year agoHow to Reduce the Cost of Clinical Trial Supply Chain While Maintaining Quality and Efficiency
Clinical trial supply chain is a critical component of drug development, ensuring that drugs are available for testing, regulatory approval, and distribution. However, managing this supply chain can be challenging, with factors such as cost, quality, and efficiency all coming...
1 year ago
Raising Representation in Clinical Trials: An Interview with Liz Beatty, Inato
The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...
3 years agoRaising Representation in Clinical Trials: An Interview with Liz Beatty, Inato
The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...
3 years ago
How Predictive Modelling Can Change Personalised Medicine
Personalised medicine - treatments which focus on the individual patient or sub-population, not simply prescribing a generic treatment to a large swathe of patients - has been a key target in healthcare for a long time now. New technologies, including...
3 years agoHow Predictive Modelling Can Change Personalised Medicine
Personalised medicine - treatments which focus on the individual patient or sub-population, not simply prescribing a generic treatment to a large swathe of patients - has been a key target in healthcare for a long time now. New technologies, including...
3 years ago